皮脂代谢性炎症介导的痤疮相关受体研究进展

宋玮1, 滕政闻2, 周水涵1, 肖敏1, 张永3

【作者机构】 1成都中医药大学附属医院皮肤科; 2北京中医药大学东方医院皮肤科; 3四川省中医药科学院中医研究所中药药理研究室
【分 类 号】 R758.73
【基    金】 四川省科技计划项目(2022YFS0381)。
全文 参考文献 出版信息
皮脂代谢性炎症介导的痤疮相关受体研究进展

皮脂代谢性炎症介导的痤疮相关受体研究进展

宋 玮1 滕政闻2 周水涵1 肖 敏1 张 永3

1.成都中医药大学附属医院皮肤科,四川成都 610072;2.北京中医药大学东方医院皮肤科,北京 100078;3.四川省中医药科学院中医研究所中药药理研究室,四川成都 610031

[摘要] 痤疮是累及毛囊皮脂腺的慢性炎症性皮肤病,皮脂代谢紊乱为其发病的原因之一。皮脂代谢紊乱引发的皮肤屏障功能受损是痤疮炎症性皮损的致病关键。皮脂分泌异常与高水平炎症因子相互影响,导致痤疮病情不断加重。痤疮相关受体可调控皮脂代谢和炎症信号通路,其受体具体包括雄激素受体、胰岛素样生长因子-1受体、过氧化物酶体增殖物激活受体、Toll样受体、肝脏X受体、维生素D受体等。本文综述痤疮相关受体的研究进展,以期为痤疮的预防及治疗提供靶标。

[关键词] 痤疮;皮脂代谢;炎症;受体;发病机制

痤疮是多因素联合作用导致的毛囊皮脂腺单位慢性炎症性皮肤病,其以皮肤出现散在性粉刺、丘疹、脓疱、结节、囊肿及瘢痕等损害,且常伴皮脂溢出为临床特征[1-2]。现代医学认为,痤疮发病主要与皮脂分泌增多、痤疮丙酸杆菌增殖、毛囊皮脂腺导管的角化异常及皮肤炎症反应等有关[3-5]。目前多以抗雄激素、异维A酸、抗生素和皮质类固醇疗法,并配合化学剥脱、光动力等相关外治法辅助治疗[6]。但长期口服抗雄激素药物具有诱发深静脉血栓的风险[7];异维A酸虽能抑制皮脂腺分泌,但其具有干燥、致畸等不良反应[8-9];抗生素的滥用导致痤疮丙酸杆菌耐药,更增加痤疮治疗的难度[10]。因此,针对痤疮治疗靶标进一步研发特效药具有重要意义。近年来,痤疮发病相关受体成为研究热点,雄激素受体(androgen receptor,AR)、胰岛素样生长因子-1受体(insulin-like growth factor-1 receptor,IGF-1R)、过氧化物酶体增殖物激活受体(peroxisome-proliferator-activated receptor,PPAR)、Toll样受体(Toll-like receptor,TLR)、肝脏X受体(liver X receptor,LXR)、维生素D受体(vitamin D receptor,VDR)等在痤疮不同环节参与痤疮的发生和发展。本文总结痤疮发病相关受体,为痤疮药物的研发提供参考。

1 痤疮皮损中脂质的变化

皮肤表面的皮脂是一个动态、复杂的生态系统,主要由甘油三酯、游离脂肪酸、角鲨烯和蜡脂构成[11]。其中甘油三酯是皮脂的主要成分,由皮脂腺细胞合成,通过毛囊导管分泌到皮肤表面。皮脂中的甘油三酯不会以原形长时间停留在皮肤上,可迅速被痤疮丙酸杆菌等皮肤常驻菌群分泌的脂肪酸水解,分解生成游离脂肪酸和甘油等。角鲨烯是人类皮脂腺特有的脂质,在鲨烯合成酶的作用下生成皮肤胆固醇[12]。蜡脂是人类皮脂中的特有成分,其化学结构与甘油三酯相比更稳定,具有较强的抗氧化功能[13]。

痤疮的发病与皮脂成分的变化密切相关。皮脂中游离脂肪酸是饱和脂肪酸与不饱和脂肪酸的混合物,若两者比例失调,不饱和脂肪酸增加则改变表皮角质细胞的钙动态,并诱导毛囊异常角化[14]。亚油酸属于不饱和脂肪酸,其有维持表皮屏障的作用。研究显示,痤疮患者皮肤表面的脂质中亚油酸水平降低,导致表皮功能障碍,炎症介质渗透,进而加重痤疮[15]。痤疮患者皮脂特征是存在过氧化脂质,主要是角鲨烯过氧化。角鲨烯过氧化可刺激角质形成细胞的增殖和脂氧合酶的活性,进而导致白细胞介素-6高表达,参与痤疮炎症的发展[16]。蜡脂的合成机制尚未完全明确,但发现甘油二酯酰基转移酶1缺乏的大鼠皮肤脂质中无蜡脂,推测甘油二酯酰基转移酶1与蜡脂的合成相关[17]。甘油二酯酰基转移酶1在青春期增多,可能是痤疮发病的原因之一。

痤疮丙酸杆菌是皮肤微生态的重要组成部分,其菌群失衡可影响到表皮脂质的代谢,主要体现在以下3个方面:①痤疮丙酸杆菌的生物膜可渗透皮脂中,使角质形成细胞的凝聚力出现异常,以及分化、增殖过程紊乱,导致毛囊导管堵塞,进而微粉刺形成[18]。②痤疮丙酸杆菌通过水解皮脂中的甘油三酯产生游离脂肪酸,进而刺激毛囊产生炎症。③痤疮丙酸杆菌通过促肾上腺皮质激素释放激素及其受体途径刺激皮脂腺,并释放促炎性细胞因子。

2 皮脂代谢性炎症介导的痤疮相关受体

皮肤脂质成分变化、代谢相关酶活性异常及皮肤微生态的紊乱均可导致皮肤屏障功能受损。皮肤脂质分泌异常引发皮肤炎症,高水平炎症因子进一步加重脂质紊乱。痤疮相关受体作为调控皮脂代谢性炎症重要的信号转导分子,对痤疮的发生和发展起关键作用。

2.1 AR

雄激素对皮肤的作用主要通过AR介导。AR是一种配体依赖的核转录因子,也是类固醇激素核受体超家族的成员,其配体是睾酮、双氢睾酮等活性雄激素[19]。AR在皮肤表皮角质形成细胞、真皮成纤维细胞、毛囊外毛根鞘的基底细胞和皮脂腺细胞等均有表达[20]。痤疮是雄激素介导的皮肤病中典型的例子,其导致痤疮的机制包括3个方面:①当AR与配体结合后,AR从胞质移位到细胞核,并作为转录因子调节其靶基因的表达,进而皮脂腺细胞的增殖和分化[21]。②AR可通过增加固醇调节元件结合蛋白-1的表达,促进皮脂分泌增多[22]。③AR与活性雄激素结合能刺激巨噬细胞和中性粒细胞的炎症反应,促炎性细胞因子分泌导致的局部炎症又进一步加剧雄激素水平异常,形成恶性循环[23]。总之,AR与配体的结合不仅能增强皮脂腺的活性,还可加剧痤疮的炎症。

2.2 IGF-1R

IGF-1R是一种生长激素依赖性多肽,在皮肤中主要由真皮成纤维细胞产生,也是表皮细胞增殖和分化所必需的细胞因子[24]。研究显示,血浆IGF-1R水平与痤疮严重程度呈正相关,其发病机制包括3个方面[25]。①高水平IGF-1R可刺激5α-还原酶的合成,促进雄激素释放,并影响AR的信号转导,进而增加皮脂分泌,导致毛囊口角化过度而诱发痤疮[26]。②转录因子SRY-盒包含蛋白9的高表达主要集中在皮脂腺基底层,其在皮脂腺的发育及稳态中起关键作用。研究显示,IGF-1R可上调细胞转录因子转录因子SRY-盒包含蛋白9的表达,促进皮脂腺分泌皮脂[27]。③胰岛素样生长因子结合蛋白-3能保护IGF-1R免受降解。若胰岛素样生长因子结合蛋白-3表达下调,则IGF-1R则与其受体相结合,进而促进皮脂腺细胞的角化过度,加剧痤疮病情[28]。总之,IGF-1R在痤疮的发病机制中主要参与皮脂腺导管的过度角化。

2.3 PPAR

PPAR属于核激素受体家族,脂肪酸及其衍生物为其配体。PPAR与配体结合被激活,与类视黄醇X受体(retinoid X receptor,RXR)形成异二聚体,PPAR/RXR二聚体与靶基因启动子上游的PPAR反应元件结合,进而调节角质形成细胞增殖分化,维持皮脂代谢稳态[29]。PPAR包含PPARα、PPARβ/δ和PPARγ3种亚型,三者在表皮基底层具有表达[30]。研究显示,PPARα与PPAR-β/δ激活在体内和体外均可刺激角质形成细胞分化,参与调节皮肤表皮屏障,并具有抗炎作用[31]。Dozsa等[32]研究显示,痤疮患者皮脂腺细胞中PPARγ及其靶基因的表达水平降低,而其配体花生四烯酸升高,提示PPARγ可能防止脂质蓄积和炎症反应。PPARγ还可通过环氧合酶-2途径,减少炎症介质前列腺素E2的产生,从而介导雄激素对皮脂腺功能的调控和炎症反应的发生[33]。综上所述,PPAR具有抗炎、有效纠正毛囊角化的功能,是痤疮的保护因素,可能成为痤疮评估和治疗的靶标。

2.4 TLR

TLR是与先天免疫反应相关的跨膜受体,包括胞外区、跨膜区和胞内区,其中胞外区与病原相关分子模式的识别和结合有关,胞内区与信号转导有关,与痤疮密切相关的主要是TLR2。与在痤疮患者中,TLR2表达于角质形成细胞、皮脂腺细胞和巨噬细胞等[34]。痤疮丙酸杆菌可被TLR2识别,并通过激活TLR2胞内区的髓样分化因子88依赖性途径,诱导并激活NF-κB、MAPK等多种信号通路,进而释放白细胞介素-1α、白细胞介素-8、白细胞介素-12等促炎性细胞因子,激发级联效应,启动痤疮免疫炎症反应[35]。痤疮严重程度与TLR2信号表达强度呈正相关[36]。因此,临床上维甲酸类药物可通过下调TLR2信号通路抑制痤疮的炎症反应[37]。TLR2基因的多态性与痤疮发病的危险性相关。TLR2 Arg753Gln的753Gln等位基因是中国汉族患者痤疮的风险因子,但还需进一步证实[38]。

2.5 LXR

LXR是表皮脂质合成的关键调控因子之一,包括LXRα和LXRβ两种亚型。LXRα在调节先天免疫、炎症反应等方面发挥重要作用,而LXRβ主要参与角质形成细胞分化及表皮渗透屏障功能[39]。LXRα可表达在表皮角质形成细胞和成纤维细胞中,由胆固醇的氧化衍生物和胆固醇生物合成中间体激活。LXRα的激活可刺激表皮屏障形成所需的脂质合成,其机制为LXRα诱导PPAR和固醇调节元件结合蛋白-1的表达,进而导致NF-κB活化,促进皮脂形成[40]。LXRβ通过多种机制刺激角质形成细胞分化和发展渗透屏障动态平衡,包括激活表皮脂肪产生,增强角质层细胞外脂肪合成所必需的酶活性等。LXRα和LXRβ均可与RXR相互作用形成异二聚体,并直接结合到LXR反应元件上,调控基因转录,主要诱导三磷酸腺苷结合盒转运体的表达,进而促进脂肪酸代谢[41]。总之,LXR被激活后具有“胆固醇逆向转运”与“脂质合成”的双重作用。

2.6 VDR

VDR是脂溶性类固醇激素受体家族的成员。在角质形成细胞中,维生素D被转化为其活性形式1,25-二羟维生素D3,与VDR相互结合后,再与视黄酸受体形成异二聚体复合物,然后被募集到靶基因启动子中维生素D反应元件调控靶基因表达[42]。VDR是痤疮的保护因素,其治疗痤疮的机制主要有以下4个方面:①局部应用维生素D制剂使角质形成细胞与1,25-二羟维生素D3孵育后,可显著降低痤疮皮损中白细胞介素-6、白细胞介素-8和白细胞介素-1β水平,提示VDR与配体结合后具有较强的抗炎作用[43]。②体外高水平1,25-二羟维生素D3对皮脂腺细胞生长有抑制作用,提示其可通过减少皮脂分泌治疗痤疮[44]。③角质形成细胞上的VDR与1,25-二羟维生素D3结合后,可抑制β-连环蛋白的转录活性,从而抑制角质形成细胞增殖,起到治疗痤疮的作用[45]。④VDR的两个相邻单核苷酸多态性ApaI和TaqI在痤疮发病中起作用,其中A等位基因和AATT结合基因对痤疮发展有保护作用,而TT基因型和t等位基因可增加痤疮的风险[46]。

3 小结

本文总结皮脂代谢紊乱介导的痤疮发病相关受体,其中AR、IGF-1R、TLR是痤疮的危险因素,而PPAR、LXR、VDR是保护因素。目前对痤疮受体的探索仍缺乏多中心、大样本量的随机对照临床数据,仍需进一步明确痤疮受体的调控机制及基因多态性,以期为开发更高效、安全的痤疮治疗靶向药物提供帮助。

利益冲突声明:所有作者均声明不存在利益冲突。

[参考文献]

[1] 崔勇,高兴华. 皮肤性病学[M]. 10版. 南京:人民卫生出版社,2024.

[2] Zhang X,Zhang Z,Tao H,et al. Comprehensive assessment of the efficacy and safety of a clay mask in oily and acne skin [J]. Skin Res Technol,2023,29(11):e13513.

[3] 张娟娟,朱明芳. 中西医调节皮脂代谢治疗痤疮的研究进展[J]. 中国美容医学,2026,35(2):168-171.

[4] Hu T,Wei Z,Ju Q,et al. Sex hormones and acne:state of the art [J]. J Dtsch Dermatol Ges,2021,19(4):509-515.

[5] 蓝月珑,张祥银,周耀辉,等. 皮肤微生物群与痤疮[J].皮肤病与性病,2025,47(5):299-304.

[6] 易雪晴,王琳梓,方玉甫. 中医药治疗痤疮的现状及研究进展[J]. 中国美容医学,2025,34(5):189-193.

[7] Huang F X,Zheng J,Fan Z. Clinical study on thromboembolic events in prostate cancer patients receiving radiation therapy with or without androgen deprivation therapy [J].Ann Ital Chir,2025,96(4):533-542.

[8] 李泳蓉. 重度痤疮临床特征及异维A酸联合水杨酸治疗的临床分析[D]. 昆明:大理大学,2023.

[9] 殷桃,徐永梓,谢艳秋. 口服异维A酸联合中医药治疗痤疮的研究进展[J]. 中国中西医结合皮肤性病学杂志,2024,23(1):92-95.

[10] 高睿迪,李双凤,张振东,等. 痤疮丙酸杆菌的耐药性研究进展[J]. 临床皮肤科杂志,2024,53(8):488-490.

[11] Bi Y,Pang S,Liu Y,et al. Aquaporins in lipid metabolism:functions and regulation in health and disease [J].Lipids Health Dis,2025,24(1):336-342.

[12] Qi L,Li X,Ren Y,et al. A facile workflow for sebum fatty acids and squalene identification via advanced lipidomic methodologies [J]. Anal Chem,2025,97(18):9664-9674.

[13] Miner K,Murphy R,Steiss S,et al. Lipid dysregulation in sebaceous gland disorders and the impact of sphingolipid metabolism on acne pathogenesis [J]. Cureus,2025,17(4):e82463.

[14] Paraskevopoulos G,Opalka L,Kovacik A,et al. Lysosphingolipids in ceramide deficient skin lipid models [J].J Lipid Res,2025,66(1):722-728.

[15] Kim B R,Kim G,Jin S P,et al. Causal association between polyunsaturated fatty acids and acne:a twosample Mendelian randomization study [J]. Br J Dermatol,2025,192(6):1106-1114.

[16] Condrò G,Sciortino R,Perugini P. Squalene peroxidation and biophysical parameters in acne-prone skin:a pilot“in vivo” study [J]. Pharmaceuticals(Basel),2023,16(12):1704-1712.

[17] Yorgun A M,Kogler H,Abolhassani H,et al. Clinical and immunological prognostic factors with novel variants in a large cohort of diacylglycerol acyltransferase 1 deficiency [J]. J Allergy Clin Immunol Pract,2025,13(9):2449-2459.

[18] 曾小芳,许爱娥. 微粉刺研究新进展[J]. 中国中西医结合皮肤性病学杂志,2023,22(3):296-298.

[19] An S,Zheng M,Park I G,et al. Differential expression of androgen receptor and 5-α reductase isoforms in skin cells [J]. Arch Dermatol Res,2024,317(1):138.

[20] Nabel C S,Sussman C B,Whittaker C A,et al. Brief report:androgen receptor expression is associated with male predominance in thymic neuroendocrine neoplasms [J]. JTO Clin Res Rep,2026,7(4):100973-100985.

[21] Sanchez C,Keri J. Androgen receptor inhibitors in the treatment of acne vulgaris:efficacy and safety profiles of clascoterone 1% cream [J]. Clin Cosmet Investig Dermatol,2022,15(3):1357-1366.

[22] Gu H,An H J,Gwon M G,et al. The effects of synthetic SREBP-1 and PPAR-γ decoy oligodeoxynucleotide on acne-like disease in vivo and in vitro via lipogenic regulation [J]. Biomolecules,2022,12(12):1858-1869.

[23] Hu T,Wei Z,Ju Q,et al. Sex hormones and acne:state of the art [J]. J Dtsch Dermatol Ges,2021,19(4):509-515.

[24] Wen S Y,Ng S C,Noriega L,et al. Echinacoside promotes collagen synthesis and survival via activation of IGF-1 signaling to alleviate UVB-induced dermal fibroblast photoaging [J]. Biofactors,2025,51(1):e2152.

[25] Fan M,Lai Y,Fan X,et al. Potential role of insulin-like growth factor 1 and growth hormone in acneiform eruptions:evidence from a rat model of acromegaly [J]. J Endocrinol Invest,2025,13(9):2449-2459.

[26] Li J,Mao B,Tang X,et al. Endocrine and metabolic drivers of sebum dysregulation:mechanisms and therapeutic strategies [J]. Life Sci,2025,38(3):124044-124052.

[27] Shi G,Wang T T,Quan J H,et al. Sox9 facilitates proliferation,differentiation and lipogenesis in primary cultured human sebocytes [J]. J Dermatol Sci,2017,85(1):44-50.

[28] Shah R,Bansal D,Rastogi P,et al. Normative data for insulin-like growth factor-1 and insulin-like growth factor binding protein-3 and their determinants in healthy adult males from India:the INDIIGo study [J]. Sci Rep,2025,15(1):41340-41353.

[29] Zou J,Song Q,Shaw P C,et al. Dendrobium officinale regulate lipid metabolism in diabetic mouse liver via PPAR-RXR signaling pathway:evidence from an integrated multi-omics analysis [J]. Biomed Pharmacother,2024,173:116395.

[30] Strosznajder A K,Wójtowicz S,Jeżyna M J,et al. Recent insights on the role of PPAR-β/δ in neuroinflammation and neurodegeneration,and its potential target for therapy [J]. Neuromolecular Med,2021,23(1):86-98.

[31] Wallmeyer L,Lehnen D,Eger N,et al. Stimulation of PPARα normalizes the skin lipid ratio and improves the skin barrier of normal and filaggrin deficient reconstructed skin [J]. J Dermatol Sci,2015,80(2):102-110.

[32] Dozsa A,Mihaly J,Dezso B,et al. Decreased peroxisome proliferator-activated receptor γ level and signalling in sebaceous glands of patients with acne vulgaris [J]. Clin Exp Dermatol,2016,41(5):547-551.

[33] Ahmad I,Hasan M,Bhowmik D R,et al. Modulation of adiposity and adipocyte inflammation by methanol extracts of Alpinia calcarata leaf in high-fat-diet inducedobese mice:involvement of COX-2 and PPAR-γ [J]. Heliyon,2025,11(2):e41949.

[34] Cho O,Watanabe K,Sugita T. Fungal-bacterial crosstalk modulates glucocorticoid primed TLR2 signaling in the human skin [J]. Microorganisms,2025,13(9):450-463.

[35] He Y,Wang W,Jiang J,et al. Infliximab inhibits TNF-α-dependent activation of the NLRP3/IL-1β pathway in acne inversa [J]. Heliyon,2024,10(12):e33146.

[36] 黄青,翁家俊,黄港,等. 基于TLR2介导的炎症通路探讨温清饮对湿热体质寻常性痤疮的疗效及作用机制[J]. 中华中医药杂志,2021,36(9):5677-5682.

[37] Martinez R,Mayur O,Pagani K,et al. Topical tretinoin alters skin microbiota in patients with mild acne [J]. JAAD Int,2024,14(6):1-3.

[38] Tian L M,Xie H F,Yang T,et al. Association study of tumor necrosis factor receptor type 2 M196R and toll-like receptor 2 Arg753Gln polymorphisms with acne vulgaris in a Chinese Han ethnic group [J]. Dermatology,2010,221(3):276-284.

[39] Slominski A T,Kim T K,Qayyum S,et al. Vitamin D and lumisterol derivatives can act on liver X receptors(LXRs) [J]. Sci Rep,2021,11(1):8002-8008.

[40] Liu S,Luo X H,Liu Y F,et al. Emodin exhibits anti-acne potential by inhibiting cell growth,lipogenesis,and inflammation in human SZ95 sebocytes [J]. Sci Rep,2023,13(1):576-584.

[41] Jurutka P W,Martino O,Reshi S,et al. An isochroman analog of CD3254 and allyl-,isochroman-analogs of NEt-TMN prove to be more potent retinoid-X-receptor(RXR) selective agonists than bexarotene [J]. Int J Mol Sci,2022,23(24):16213-16220.

[42] Stanisic T,Ewing E U,Lindell A,et al. Vitamin D3-VDR and vitamin A-RAR affect IL-13 and IFNγ secretion from human CD4+ T cells directly and indirectly via competition for their shared co-receptor RXR [J]. Scand J Immunol,2025,101(1):e13429.

[43] Dahlan N H,Sitohang I B S,Indriatmi W,et al. Correlation between reduced IL-1β levels in acne lesions and the decrease in acne inflammatory lesions following topical vitamin D administration:a double-blind randomized controlled trial [J]. Clin Cosmet Investig Dermatol,2024,17(3):2183-2195.

[44] Grieco T,Paolino G,Moliterni E,et al. Non-skeletal roles of vitamin D in skin,gut,and cardiovascular disease:focus on epithelial barrier function and immune regulation in chronic disease [J]. Int J Mol Sci,2025,26(17):60-71.

[45] Gao H,Xie T,Zhang Y,et al. Vitamin D and the aging skin:insights into oxidative stress,inflammation,and barrier function [J]. Immun Ageing,2025,22(1):49-55.

[46] Swelam M M,El-Barbary R A H,Saudi W M,et al. Associations among two vitamin D receptor (VDR) gene polymorphisms (ApaI and TaqI) in acne vulgaris:a pilot susceptibility study [J]. J Cosmet Dermatol,2019,18(4):1113-1120.

Research progress on acne-related receptors mediated by sebum metabolic inflammation

SONG Wei1 TENG Zhengwen2 ZHOU Shuihan1 XIAO Min1 ZAHNG Yong3

1.Department of Dermatology, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Sichuan Province, Chengdu 610072, China; 2.Department of Dermatology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China; 3.Traditional Chinese Medicine Pharmacology Research Laboratory, Institute of Traditional Chinese Medicine, Sichuan Academy of Chinese Medicine Sciences, Sichuan Province, Chengdu 610031,China

[Abstract] Acne is a chronic inflammatory skin disease that affects hair follicles and sebaceous glands, one of the causes of its occurrence is the disorder of sebum metabolism. The impairment of skin barrier function caused by dermal lipid metabolism disorders is also a key factor contributing to inflammatory skin lesions of acne. Abnormal secretion of skin lipids and high levels of inflammatory factors interact with each other, leading to continuous aggravation of acne.The acne-related receptors can regulate sebum metabolism and inflammatory signaling pathways, specific receptors include androgen receptor, insulin-like growth factor-1 receptor, peroxisome proliferator-activated receptor, Toll-like receptor, liver X receptor, and vitamin D receptor. This article reviews research progress of acne-related receptors, the aim of providing targets for the prevention and treatment of acne.

[Key words] Acne; Sebum metabolism; Inflammation; Receptor; Pathogenesis

[中图分类号] R758.73

[文献标识码] A

[文章编号] 1673-7210(2026)08(c)-0193-05

DOI:10.20047/j.issn1673-7210.25122096

[基金项目] 四川省科技计划项目(2022YFS0381)。

[作者简介] 宋玮(1993-),男,博士;研究方向:中医药防治皮肤病。

[通信作者] 张永(1988-),男,博士,副研究员;研究方向:中医药防治脂代谢异常疾病。

(收稿日期:2025-12-27)

(修回日期:2026-03-19)

X